Published in J Virol on May 29, 2013
IFITMs restrict the replication of multiple pathogenic viruses. J Mol Biol (2013) 1.52
IFITM3 restricts influenza A virus entry by blocking the formation of fusion pores following virus-endosome hemifusion. PLoS Pathog (2014) 1.42
HIV-1 entry in SupT1-R5, CEM-ss, and primary CD4+ T cells occurs at the plasma membrane and does not require endocytosis. J Virol (2014) 1.14
Interferon-induced transmembrane protein 3 is a type II transmembrane protein. J Biol Chem (2013) 1.11
IFITM-Family Proteins: The Cell's First Line of Antiviral Defense. Annu Rev Virol (2014) 1.08
Amphotericin B increases influenza A virus infection by preventing IFITM3-mediated restriction. Cell Rep (2013) 1.08
Interferon induction of IFITM proteins promotes infection by human coronavirus OC43. Proc Natl Acad Sci U S A (2014) 1.04
IFITM proteins are incorporated onto HIV-1 virion particles and negatively imprint their infectivity. Retrovirology (2014) 1.01
Phosphorylation of the antiviral protein interferon-inducible transmembrane protein 3 (IFITM3) dually regulates its endocytosis and ubiquitination. J Biol Chem (2014) 1.00
The antiviral restriction factors IFITM1, 2 and 3 do not inhibit infection of human papillomavirus, cytomegalovirus and adenovirus. PLoS One (2014) 0.99
The major cellular sterol regulatory pathway is required for Andes virus infection. PLoS Pathog (2014) 0.98
Defining the range of pathogens susceptible to Ifitm3 restriction using a knockout mouse model. PLoS One (2013) 0.95
Emerging roles of interferon-stimulated genes in the innate immune response to hepatitis C virus infection. Cell Mol Immunol (2014) 0.94
IFITM3 polymorphism rs12252-C restricts influenza A viruses. PLoS One (2014) 0.94
Phleboviruses and the Type I Interferon Response. Viruses (2016) 0.90
Primate lentiviruses are differentially inhibited by interferon-induced transmembrane proteins. Virology (2014) 0.89
HIV-1 mutates to evade IFITM1 restriction. Virology (2014) 0.89
Encephalitic Arboviruses: Emergence, Clinical Presentation, and Neuropathogenesis. Neurotherapeutics (2016) 0.89
Human cytomegalovirus exploits interferon-induced transmembrane proteins to facilitate morphogenesis of the virion assembly compartment. J Virol (2014) 0.88
Simian hemorrhagic fever virus cell entry is dependent on CD163 and uses a clathrin-mediated endocytosis-like pathway. J Virol (2014) 0.86
Interferon-Inducible Transmembrane Protein 3 Genetic Variant rs12252 and Influenza Susceptibility and Severity: A Meta-Analysis. PLoS One (2015) 0.85
The Interferon-Stimulated Gene Ifitm3 Restricts West Nile Virus Infection and Pathogenesis. J Virol (2016) 0.83
Regulation of the trafficking and antiviral activity of IFITM3 by post-translational modifications. Future Microbiol (2014) 0.83
A sorting signal suppresses IFITM1 restriction of viral entry. J Biol Chem (2014) 0.83
The Interferon-Stimulated Gene IFITM3 Restricts Infection and Pathogenesis of Arthritogenic and Encephalitic Alphaviruses. J Virol (2016) 0.82
The C-terminal sequence of IFITM1 regulates its anti-HIV-1 activity. PLoS One (2015) 0.81
Interplay between the Virus and Host in Rift Valley Fever Pathogenesis. J Innate Immun (2015) 0.81
Cellular Antiviral Factors that Target Particle Infectivity of HIV-1. Curr HIV Res (2016) 0.80
siRNA Screen Identifies Trafficking Host Factors that Modulate Alphavirus Infection. PLoS Pathog (2016) 0.80
Protein Kinase R Degradation Is Essential for Rift Valley Fever Virus Infection and Is Regulated by SKP1-CUL1-F-box (SCF)FBXW11-NSs E3 Ligase. PLoS Pathog (2016) 0.80
High content image-based screening of a protease inhibitor library reveals compounds broadly active against Rift Valley fever virus and other highly pathogenic RNA viruses. PLoS Negl Trop Dis (2014) 0.80
Bat and pig IFN-induced transmembrane protein 3 restrict cell entry by influenza virus and lyssaviruses. J Gen Virol (2015) 0.79
Duck Interferon-Inducible Transmembrane Protein 3 Mediates Restriction of Influenza Viruses. J Virol (2015) 0.79
Lipid interactions during virus entry and infection. Cell Microbiol (2014) 0.78
The Role of Phlebovirus Glycoproteins in Viral Entry, Assembly and Release. Viruses (2016) 0.77
The V3-loop of HIV-1 Env determines viral susceptibility to IFITM3 impairment of viral infectivity. J Virol (2017) 0.76
A Role for IFITM Proteins in Restriction of Mycobacterium tuberculosis Infection. Cell Rep (2015) 0.75
Differential host gene responses from infection with neurovirulent and partially-neurovirulent strains of Venezuelan equine encephalitis virus. BMC Infect Dis (2017) 0.75
Interferon-Induced Transmembrane Protein 3 Inhibits Hantaan Virus Infection, and Its Single Nucleotide Polymorphism rs12252 Influences the Severity of Hemorrhagic Fever with Renal Syndrome. Front Immunol (2017) 0.75
Identification of Interferon-Stimulated Gene Proteins That Inhibit Human Parainfluenza Virus Type 3. J Virol (2016) 0.75
Swine interferon-inducible transmembrane proteins potently inhibit influenza A virus replication. J Virol (2014) 0.75
Interference with the production of infectious viral particles and bimodal inhibition of replication are broadly conserved antiviral properties of IFITMs. PLoS Pathog (2017) 0.75
Sorafenib impedes Rift Valley fever virus egress by inhibiting Valosin-containing protein function in the cellular secretory pathway. J Virol (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Functional role of type I and type II interferons in antiviral defense. Science (1994) 18.92
A diverse range of gene products are effectors of the type I interferon antiviral response. Nature (2011) 12.86
Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells. Cell (1984) 8.32
The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell (2009) 7.88
Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol (2002) 6.60
IFITM3 restricts the morbidity and mortality associated with influenza. Nature (2012) 4.66
Rift Valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Vet Res (2010) 3.78
A single DNA response element can confer inducibility by both alpha- and gamma-interferons. Proc Natl Acad Sci U S A (1989) 3.33
Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog (2011) 3.26
Identification of five interferon-induced cellular proteins that inhibit west nile virus and dengue virus infections. J Virol (2010) 3.10
Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am J Trop Med Hyg (1995) 3.08
IFITM3 inhibits influenza A virus infection by preventing cytosolic entry. PLoS Pathog (2011) 2.99
Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J Virol (2010) 2.98
The IFITM proteins inhibit HIV-1 infection. J Virol (2010) 2.80
Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J Gen Virol (1985) 2.71
NSs protein of rift valley fever virus induces the specific degradation of the double-stranded RNA-dependent protein kinase. J Virol (2009) 2.39
Interferon-inducible effector mechanisms in cell-autonomous immunity. Nat Rev Immunol (2012) 2.21
Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation. PLoS Pathog (2009) 2.17
The pathogenesis of Rift Valley fever. Viruses (2011) 2.02
Ifitm3 limits the severity of acute influenza in mice. PLoS Pathog (2012) 1.97
Use of reassortant viruses to map attenuating and temperature-sensitive mutations of the Rift Valley fever virus MP-12 vaccine. Vaccine (1990) 1.82
S-palmitoylation and ubiquitination differentially regulate interferon-induced transmembrane protein 3 (IFITM3)-mediated resistance to influenza virus. J Biol Chem (2012) 1.67
The N-terminal region of IFITM3 modulates its antiviral activity by regulating IFITM3 cellular localization. J Virol (2012) 1.64
Characterization of the osteoblast-specific transmembrane protein IFITM5 and analysis of IFITM5-deficient mice. J Bone Miner Metab (2010) 1.61
Evolution of vertebrate interferon inducible transmembrane proteins. BMC Genomics (2012) 1.44
Complete nucleotide sequence of the M RNA segment of Rift Valley fever virus. Virology (1985) 1.41
Proteomics computational analyses suggest that the carboxyl terminal glycoproteins of Bunyaviruses are class II viral fusion protein (beta-penetrenes). Theor Biol Med Model (2004) 1.41
Entry of bunyaviruses into mammalian cells. Cell Host Microbe (2010) 1.40
The pathology of Rift Valley fever. II. Lesions occurring in field cases in adult cattle, calves and aborted foetuses. Onderstepoort J Vet Res (1982) 1.37
The pathology of Rift Valley fever. I. Lesions occurring in natural cases in new-born lambs. Onderstepoort J Vet Res (1977) 1.30
Rift Valley fever virus structural proteins: expression, characterization and assembly of recombinant proteins. Virol J (2008) 1.30
Type I interferons and the innate immune response--more than just antiviral cytokines. Mol Immunol (2005) 1.26
Prevention of Rift Valley fever in rhesus monkeys with interferon-alpha. Rev Infect Dis (1989) 1.22
Rift valley fever: recent insights into pathogenesis and prevention. J Virol (2011) 1.21
Bunyavirus: structure and replication. Adv Exp Med Biol (2012) 1.20
Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines. Antiviral Res (2009) 1.16
Viral determinants of virulence for Rift Valley fever (RVF) in rats. Microb Pathog (1988) 1.13
Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus. Virology (2009) 1.13
Rift valley fever virus infection of human cells and insect hosts is promoted by protein kinase C epsilon. PLoS One (2010) 1.09
Rapid accumulation of virulent rift valley Fever virus in mice from an attenuated virus carrying a single nucleotide substitution in the m RNA. PLoS One (2010) 1.05
Development and characterization of a Rift Valley fever virus cell-cell fusion assay using alphavirus replicon vectors. Virology (2006) 1.04
Cell fusion activities of Hantaan virus envelope glycoproteins. J Virol (2004) 1.01
Crimean-Congo hemorrhagic fever virus entry and replication is clathrin-, pH- and cholesterol-dependent. J Gen Virol (2009) 0.99
An assembly model of rift valley Fever virus. Front Microbiol (2012) 0.97
Recombinant human interferon-gamma modulates Rift Valley fever virus infection in the rhesus monkey. J Interferon Res (1991) 0.97
Study of Andes virus entry and neutralization using a pseudovirion system. J Virol Methods (2009) 0.96
Heparan sulfate facilitates Rift Valley fever virus entry into the cell. J Virol (2012) 0.94
Biochemical characterization of Rift Valley fever virus. Virology (1980) 0.92
La Crosse bunyavirus can mediate pH-dependent fusion from without. Virology (1984) 0.91
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature (2003) 8.77
The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell (2009) 7.88
Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell (2008) 6.37
Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity (2008) 5.86
Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc Natl Acad Sci U S A (2004) 5.15
Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe (2009) 5.12
Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science (2005) 4.97
Ovarian tumor domain-containing viral proteases evade ubiquitin- and ISG15-dependent innate immune responses. Cell Host Microbe (2007) 4.14
A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem (2003) 3.60
Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog (2011) 3.26
Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med (2010) 3.25
Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci U S A (2004) 3.23
The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat Rev Immunol (2012) 3.17
Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis (2003) 3.15
Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J (2005) 3.14
Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses. Nature (2007) 3.06
Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell (2003) 3.03
Molecular Evidence of Sexual Transmission of Ebola Virus. N Engl J Med (2015) 2.71
Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis (2007) 2.68
Release of autoinhibition converts ESCRT-III components into potent inhibitors of HIV-1 budding. Proc Natl Acad Sci U S A (2006) 2.63
Evaluation of perceived threat differences posed by filovirus variants. Biosecur Bioterror (2011) 2.62
A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology (2005) 2.60
Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor. J Biol Chem (2006) 2.56
Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J Virol (2002) 2.43
SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells. J Biol Chem (2005) 2.36
Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization. Proc Natl Acad Sci U S A (2005) 2.35
In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding. Proc Natl Acad Sci U S A (2003) 2.32
Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates. Nat Med (2002) 2.20
Evolution of a TRIM5-CypA splice isoform in old world monkeys. PLoS Pathog (2008) 2.20
Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci U S A (2003) 2.18
The primed ebolavirus glycoprotein (19-kilodalton GP1,2): sequence and residues critical for host cell binding. J Virol (2009) 2.15
High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A (2011) 2.14
Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog (2006) 2.01
Ifitm3 limits the severity of acute influenza in mice. PLoS Pathog (2012) 1.97
PHLPP-1 negatively regulates Akt activity and survival in the heart. Circ Res (2010) 1.93
Practical lessons from global safe motherhood initiatives: time for a new focus on implementation. Lancet (2007) 1.91
Animal origins of the severe acute respiratory syndrome coronavirus: insight from ACE2-S-protein interactions. J Virol (2006) 1.91
Identification of small molecule inhibitors of anthrax lethal factor. Nat Struct Mol Biol (2003) 1.86
The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry. Cell Host Microbe (2013) 1.86
Ligand-independent dimerization of CXCR4, a principal HIV-1 coreceptor. J Biol Chem (2002) 1.82
Reemergence of monkeypox: prevalence, diagnostics, and countermeasures. Clin Infect Dis (2005) 1.82
Influenza A virus neuraminidase limits viral superinfection. J Virol (2008) 1.79
The evolving field of biodefence: therapeutic developments and diagnostics. Nat Rev Drug Discov (2005) 1.79
Dendritic cells endocytose Bacillus anthracis spores: implications for anthrax pathogenesis. J Immunol (2005) 1.78
Ribavirin causes error catastrophe during Hantaan virus replication. J Virol (2003) 1.78
Sulphated tyrosines mediate association of chemokines and Plasmodium vivax Duffy binding protein with the Duffy antigen/receptor for chemokines (DARC). Mol Microbiol (2005) 1.71
Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J Immunol (2005) 1.69
Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun (2004) 1.67
Novel broad-spectrum bis-(imidazolinylindole) derivatives with potent antibacterial activities against antibiotic-resistant strains. Antimicrob Agents Chemother (2009) 1.66
VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob Agents Chemother (2006) 1.63
Development and characterization of a mouse model for Marburg hemorrhagic fever. J Virol (2009) 1.62
Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Arch Virol (2012) 1.59
Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein. FEMS Immunol Med Microbiol (2004) 1.58
Thottapalayam virus, a prototype shrewborne hantavirus. Emerg Infect Dis (2007) 1.57
Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. J Virol (2005) 1.54
Exceptional simian hemorrhagic fever virus diversity in a wild African primate community. J Virol (2012) 1.53
Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R. J Biol Chem (2006) 1.53
TIM-family proteins promote infection of multiple enveloped viruses through virion-associated phosphatidylserine. PLoS Pathog (2013) 1.53
Prevention of postpartum hemorrhage at home birth in Afghanistan. Int J Gynaecol Obstet (2010) 1.52
3D visualization of HIV transfer at the virological synapse between dendritic cells and T cells. Proc Natl Acad Sci U S A (2010) 1.52
Mapping binding residues in the Plasmodium vivax domain that binds Duffy antigen during red cell invasion. Mol Microbiol (2005) 1.52
Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin. J Virol (2010) 1.48
Inhibition of metalloprotease botulinum serotype A from a pseudo-peptide binding mode to a small molecule that is active in primary neurons. J Biol Chem (2006) 1.47
Receptor determinants of zoonotic transmission of New World hemorrhagic fever arenaviruses. Proc Natl Acad Sci U S A (2008) 1.47
Structural basis for receptor recognition by New World hemorrhagic fever arenaviruses. Nat Struct Mol Biol (2010) 1.46
Monitoring of Ebola Virus Makona Evolution through Establishment of Advanced Genomic Capability in Liberia. Emerg Infect Dis (2015) 1.45
Time-lapse confocal imaging of development of Bacillus anthracis in macrophages. J Infect Dis (2004) 1.44
Role of natural killer cells in innate protection against lethal ebola virus infection. J Exp Med (2004) 1.44
Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine (2005) 1.44
The RNA binding domain of the hantaan virus N protein maps to a central, conserved region. J Virol (2002) 1.40
A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One (2013) 1.38
Anthrax biosensor, protective antigen ion channel asymmetric blockade. J Biol Chem (2005) 1.37
Host-species transferrin receptor 1 orthologs are cellular receptors for nonpathogenic new world clade B arenaviruses. PLoS Pathog (2009) 1.37
Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2. J Virol (2004) 1.36
Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity. Biochem Biophys Res Commun (2003) 1.34
Conformational states of the severe acute respiratory syndrome coronavirus spike protein ectodomain. J Virol (2006) 1.34
Protein evolution with an expanded genetic code. Proc Natl Acad Sci U S A (2008) 1.32